Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial

Competing Interest Statement

JM, CH, SK, AW, AB, LB, NB, MK, VR, MJoh, EL, AR, AM, TS, MJon have no conflicts of interest to disclose. CP serves on advisory boards for AstraZeneca, Boehringer Ingelheim, Merck Sharp and Dohme and Novartis. CJ serves on advisory boards for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Sanofi-Genzyme. VJ has received grants from Baxter Healthcare, Biocon and GlaxoSmithKline, and speaker fees/advisory board from AstraZeneca, Baxter Healthcare, NephroPlus, Sanofi - all outside the submitted work. All fees paid to the organization. MJar is responsible for research projects that have received unrestricted funding from Amgen, Baxter, Bayer, CSL Behring, Eli Lilly, Gambro, and Merck Sharp and Dohme; has served on advisory boards sponsored by Akebia, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Merck Sharp and Dohme and Vifor; serves on the Steering Committee for trials sponsored by Chinook, CSL Behring and Janssen; serves on a Steering Committee for an investigator initiated trial in COVID-19 disease with funding support from Dimerix; spoken at scientific meetings sponsored by Amgen, Janssen, Roche and Vifor; with any consultancy, honoraria or travel support paid to the institution.

Clinical Trial

NCT04394117

Funding Statement

CLARITY is supported by the Australian Government's Medical Research Future Fund Respiratory Medicine Clinical Trials Research on COVID-19 2020 grant scheme (ref. no. APP2002277).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Sydney Local Health District Ethics Review Committee

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes